TECregen: Valuation, Funding & Investors
TECregen is a biotechnology company pioneering thymus rejuvenation to address conditions driven by impaired T-cell responses and immune ageing. The company develops differentiated thymopoietic biologics that revitalize and expand thymic epithelial cells (TECs) to restore immune function, support recovery after transplantation or cytotoxic therapy, and enhance immune surveillance against cancer.
Leadership & Board
- Current Number of Employees
- 14
- Current LinkedIn Followers
- 1,558
Latest Estimated Valuation
- Total Amount Raised
- $10M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $10M
- Latest Funding Round
- Seed Round
Employee Trend
TECregen had 14 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
14Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
TECregen had 1,558 followers as of October 26, 2026. The number of followers increased by 3 (0.19%) week-over-week.
1,558Latest Followers Count
3(0.19%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jan 08, 2026 | Seed Round | $10.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| CARMA Fund | Seed Round |
| Eos BioInnovation | Seed Round |
| High-Tech Gründerfonds | Seed Round |
| Boehringer Ingelheim Venture Fund | Seed Round |
| LifeSpan Vision Ventures | Seed Round |
| JFG Life Sciences Foundation of the University of Basel | Seed Round |
| Zurich Cantonal Bank | Seed Round |
Similar Companies
A snapshot of private companies similar to TECregen, helping you discover and navigate related company profiles.
Related News and Analysis
